The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The Smolka Lab, led by Prof. Marcus Smolka, molecular biology and genetics, recently published a study shedding light on a novel pathway that explains how cancer cells can become resistant to ...

Oral cancer is one of the most common head and neck cancers worldwide, with hundreds of thousands of new cases diagnosed every year. Despite advances in surgery, radiotherapy, and chemotherapy, ...

WINSTON-SALEM, N.C., Oct. 29, 2025 — Scientists at Wake Forest University School of Medicine, in collaboration with researchers at Weill Cornell Medicine, have made a breakthrough in understanding why ...

Chemotherapy-induced nausea and vomiting (CINV) represents one of the most distressing and debilitating side effects experienced by cancer patients undergoing treatment, significantly impacting ...

Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...

Hair loss is one of the most common and emotionally challenging side effects of chemotherapy, affecting self-esteem, identity, and social confidence. Known as chemotherapy-induced alopecia (CIA), it ...

Researchers recommended a tailored, scientifically validated exercise program to individuals receiving chemotherapy for ...

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression. Promising overall survival (OS) trends continued ...

Amivantamab targets EGFR and MET receptors, offering a novel approach for mCRC treatment, especially in RAS and BRAF wild-type patients. The OrigAMI-2 study compares amivantamab with standard ...